

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JOINT STOCK
COMPANY**

Số: 02/2026/CV-MED

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, January 20, 2026

To: - **State Securities Commission**
 - **Hanoi Stock Exchange**

Company Name: Mediplantex National Pharmaceutical Joint Stock Company

Address: 358 Giai Phong, Phuong Liet Ward, Hanoi

Tax code: 0100108430

Information disclosure person: Mai Nhat Thanh

Position: General Director

Pursuant to Circular No. 96/2020/TT-BTC of the Ministry of Finance on periodic information disclosure of organizations, specific explanations are provided for cases where after-tax profits differ by 10% compared to the same period last year.

Mediplantex National Pharmaceutical Joint Stock Company explains the financial statements for the fourth quarter of 2025 as follows:

- Net revenue from sales of goods and the provision of services in the fourth quarter of 2025 amounted to VND 117,611,854,279, representing an increase of 28% compared to the same period of the previous year. Gross profit from sales reached VND 27,658,612,399, up 31% year-on-year compared to the fourth quarter of 2024. This increase was mainly attributable to an improvement in the sales product mix.

- Revenue from financial activities amounted to VND 43,291,643, representing a decrease of 90% compared to the same period last year. Interest expense was VND 551,359,256, down 48% year-on-year, due to effective receivables collection and a lower average outstanding loan balance compared to the previous year.

- Selling expenses and general and administrative expenses increased at a reasonable level and at a slower pace than revenue growth, thereby contributing to improved operational efficiency.

- Other income in the fourth quarter of the current year amounted to VND 1,194,147,024, whereas no such income was recorded in the corresponding period of the previous year. This other income contributed to an increase in other profit and the Company's accounting profit before tax. Accordingly, accounting profit before tax reached VND 8,366,818,564, representing a year-on-year increase of 90%.

- As a result of the above factors, profit after corporate income tax amounted to VND 6,139,301,674, increasing by 76% compared to the same period in the fourth quarter of 2024.

Above is the explanation of Mediplantex National Pharmaceutical Joint Stock Company reporting to the State Securities Commission and Hanoi Stock Exchange on the change of indicators in the financial report of the fourth quarter of 2025 compared to the financial report of the same period last year of Mediplantex National Pharmaceutical Joint Stock Company.

Trân trọng!

Recipient:

- *As above*
- *Admin*

**MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT
STOCK COMPANY**

General Director



Mai Nhat Thanh